Literature DB >> 2388682

In vitro activity of seven azole compounds against some clinical isolates of non-dermatophytic filamentous fungi and some dermatophytes.

C A Oyeka1, H C Gugnani.   

Abstract

The in vitro activity of seven azole compounds viz clotrimozole, isoconazole, bifanazole, fluconazole oxyconazole, Bay n 7133 and Bay L 9139 was investigated against 47 clinical isolates of pathogenic non-dermatophytic filamentous fungi and dermatophytic fungi. The isolates included Hendersonula toruloidea-26, Scytalidium hyalinium-5, Scytalidium japonicum-1, Trichophyton rubrum-5, Trichophyton tonsurans-3, Trichophyton mentagrophytes var. mentagrophytes-4, Epidemophyton floccosum-2, Microporum gypseum-2 isolates. The drugs were significantly more active against the dermatophytes (MIC range 0.025-1.56 micrograms/ml) than non-dermatophytes (MIC range 0.39-6.25 micrograms/ml). Isoconazole showed more activity than the rest of the azole compound tested. Clotrimazole, fluconazole, oxyconazole, bifonazole were comparable in their inhibitory activity against both dermatophytes and non-dermatophytes. The azole derivatives, Bay n 7133 and Bay L 9139 showed higher MIC range i.e. gave a range of 0.39-1.56 micrograms/ml for dermatophytes and 1.56-6.25 micrograms/ml for non-dermatophytic filamentous fungi. The minimal fungicidal concentration (MFC) of all the drugs tested were mostly within 2-8 times their MIC values.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2388682     DOI: 10.1007/bf00437540

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  11 in total

1.  Skin and nail infection by Scytalidium hyalinum sp. nov.

Authors:  C K Campbell; J L Mulder
Journal:  Sabouraudia       Date:  1977-07

2.  Infection of the feet and nails with Hendersonula toruloidea.

Authors:  J C Gentles; E G Evans
Journal:  Sabouraudia       Date:  1970-05

3.  The action of miconazole of the growth of Candida albicans.

Authors:  H Van Den Bossche; G Willemsens; J M Van Cutsem
Journal:  Sabouraudia       Date:  1975-03

4.  Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination.

Authors:  M L Corrado; M Kramer; M Cummings; R H Eng
Journal:  Sabouraudia       Date:  1982-06

5.  In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139.

Authors:  R A Fromtling; H P Yu; S Shadomy
Journal:  Sabouraudia       Date:  1983-09

6.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

7.  [Pharmacokinetics of imidazole-antimycotics (author's transl)].

Authors:  M Plempel
Journal:  Mykosen       Date:  1980-01

8.  Antifungal activity in vitro of Ro 14-4767/002, a phenylpropyl-morpholine.

Authors:  A Polak
Journal:  Sabouraudia       Date:  1983-09

9.  Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.

Authors:  J N Galgiant; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

10.  Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400.

Authors:  D Dixon; S Shadomy; H J Shadomy; A Espinel-Ingroff; T M Kerkering
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

View more
  2 in total

Review 1.  Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal.

Authors:  L Sigler; R C Summerbell; L Poole; M Wieden; D A Sutton; M G Rinaldi; M Aguirre; G W Estes; J N Galgiani
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

2.  Phenotypic characterization of Trichophyton rubrum isolates from two geographic locations in Brazil.

Authors:  J I Dos Santos; E J Vicente; C R Paula; W Gambale
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.